Gene · 200315
APOBEC3A: apolipoprotein B mRNA editing enzyme catalytic subunit 3A
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. APOBEC3A: apolipoprotein B mRNA editing enzyme catalytic subunit 3A. Genes, record 200315. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/200315
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| P31941 | DNA dC->dU-editing enzyme APOBEC-3A | 199 | 12 | Ensembl, GeneID, HGNC |
Source UniProt
Patents358
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| EP 4828972 A1 | 2026-10-28 | 31 | P31941 | Espacenet |
| WO 2026213541 A1 | 2026-10-08 | 3 | P31941 | Espacenet |
| EP 4809080 A1 | 2026-09-23 | 82 | P31941 | Espacenet |
| JP 2026525611 A | 2026-07-31 | 63 | P31941 | Espacenet |
| JP 2026525611 A | 2026-07-31 | 76 | P31941 | Espacenet |
| JP 2026525612 A | 2026-07-31 | 496 | P31941 | Espacenet |
| JP 2026525612 A | 2026-07-31 | 509 | P31941 | Espacenet |
| EP 4777618 A1 | 2026-07-22 | 31 | P31941 | Espacenet |
| JP 2026116287 A | 2026-07-09 | 276 | P31941 | Espacenet |
| EP 4762095 A1 | 2026-06-24 | 31 | P31941 | Espacenet |
1 to 10 of 358
See all 358 patentsDrugs0
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
None in this release.
Trials0
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
None in this release.
NIH grants1,523
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | APOBEC3A papers | Newest fiscal year |
|---|---|---|---|
| P01CA234228 | APOBEC Mutagenesis in Cancer | 37 | 2025 |
| P30CA008748 | Cancer Center Support Grant | 26 | 2025 |
| T32AI083196 | Minnesota Training Program in Virology | 20 | 2025 |
| T32CA009138 | Molecular, Genetic and Cellular Targets of Cancer Training Program | 17 | 2025 |
| R37CA252081 | Molecular Mechanisms of APOBEC-Induced Mutagenesis in Cancer | 13 | 2025 |
| P30CA016672 | Cancer Center Support Grant | 11 | 2025 |
| R35GM118047 | Structural studies of viral replication and invasion | 11 | 2025 |
| RM1HG009490 | Center for Genomic Editing and Recording: Development and Application of Next-Generation Genome and Epigenome Editing Methods to Advance the Study and Treatment of Human Disease | 10 | 2025 |
| P30CA062203 | Cancer Center Support Grant | 9 | 2025 |
| R01AI150524 | Structural Basis of APOBEC Functions and HIV Restriction | 9 | 2025 |
1 to 10 of 1,523Source NIH's project files
See all 1,523 nih grantsPapers1,983
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| APOBEC3 activity and DNA polymerase-ε deficiency are associated with distinct IDH1 R132 hotspot mutations. | Mol Oncol | 2026 | 42717521 | PubTator, text mining | PubMed |
| Motif-centered analyses reveal universal and tissue-specific mutagenic mechanisms operating in the human body. | NAR Cancer | 2026 | 42707399 | PubTator, text mining | PubMed |
| pgRNA-m6A levels associate with HBV replication and liver function. | Epigenetics | 2026 | 42703000 | PubTator, text mining | PubMed |
| Fluorescence polarization-based fragment screen identifies inhibitors of APOBEC3A and APOBEC3B. | bioRxiv | 2026 | 42620011 | PubTator, text mining | PubMed |
| Distinct repair processes produce APOBEC-induced deletions, tandem substitutions, and complex mutations in yeast and human cells. | Proc Natl Acad Sci U S A | 2026 | 42520125 | PubTator, text mining | PubMed |
| Break-induced replication forms long mutable single-strand DNA during meiosis. | Nat Commun | 2026 | 42323311 | PubTator, text mining | PubMed |
| Zinc finger protein ZBTB7A suppresses hepatitis B virus replication by attenuating FXRα-mediated HBV transcription and lowering covalently closed circular DNA levels. | Antiviral Res | 2026 | 42320751 | PubTator, text mining | PubMed |
| Squamous-state excursions activate APOBEC3A in cancer. | bioRxiv | 2026 | 42244601 | PubTator, text mining | PubMed |
| Establishment and Performance Evaluation of a Multiplexed TET2-APOBEC-Mediated cfDNA Methylation Detection Workflow Using qPCR and dPCR Readouts. | J Pers Med | 2026 | 42188364 | PubTator, text mining | PubMed |
| Enhanced TLR7-induced interferon responses in women living with HIV. | Front Immunol | 2026 | 42093980 | PubTator, text mining | PubMed |
1 to 10 of 1,983
See all 1,983 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/200315
GET https://conductscience.org/api/genes/v1/200315/patents?page=2